Short-Seller’s Note is Short on Credibility, LifeMD Says

Company cites errors, distortions in anonymous “note” intended to hammer stock for quick profit

NEW YORK, April 16, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, released a letter to shareholders today in response to an error-ridden “research note” published by an entity called Culper Research. Culper is an anonymous short-seller that refuses to disclose the individuals or entities behind it.

“LifeMD uses technology to make health care more accessible to people from all walks of life. By directly providing telemedicine to patients, we help them confront the health issues that dramatically impact the quality of their lives,” said Justin Schreiber, LifeMD’s Chairman and CEO.

“We pursue this mission with transparency and integrity, so it is troubling that an anonymous short-seller would make reckless allegations about our company seemingly with the sole intent of causing a drop in our share price for his or her own personal gain. The author of this report is utterly lacking in credibility, as its numerous errors, distortions and half-truths show.”

Schreiber and the company’s CTO Stefan Galluppi jointly issued an open letter to shareholders on the company’s website (link here), in which they addressed Culper’s meritless allegations in detail. It identifies numerous errors and basic problems with the report’s credibility, including:

• Culper distorts Galluppi’s and Schreiber’s relationship with Redwood Scientific. Schreiber held a passive investment and non-controlling interest in the company, and Galluppi left the company two and a half years before it was investigated by the Federal Trade Commission.
• Culper lies about LifeMD’s licensing practices. LifeMD takes the utmost care in creating an environment that fosters the highest standard of care for our patients. LifeMD’s physician network consists of nearly 90 board-certified and monitored doctors who legally dispense prescription medications; LifeMD has never allowed an unlicensed physician to perform a telehealth consult for any of its brands. In the rare instance we discover that one of the doctors in our network has a regulatory issue, we remove that doctor immediately – as we did in the case of Dr. Badii. In the case of Dr. Kalter, he was mistakenly described as a California physician on our website. When we became aware of the web design error, we fixed it immediately. Dr. Kalter never wrote a single prescription for us in California. 
• Culper misrepresents the facts about Veritas MD, the platform we used for ~25% of all telehealth consults in Q1 and expect to be using for 100% of consults by the end of Q2. Apparently under the misimpression it was intended to be a consumer-facing app, Culper fails to understand it is our technological backbone, driving the complete and full lifecycle of patient engagement. This process extends from patient intake, patient queries and follow-ups, doctor engagement, and pharmacy services to billing. Everything we have disclosed about our LifeMD digital health platform, also known as VeritasMD, is accurate.